Use of 24-Hour Ambulatory Blood Pressure Monitoring to Assess Antihypertensive Efficacy: A Comparison of Olmesartan Medoxomil, Losartan Potassium, Valsartan, and Irbesartan

Author： Smith David H.G.   Dubiel Robert   Jones Michael  

Publisher： Adis International

ISSN： 1175-3277

Source： American Journal of Cardiovascular Drugs, Vol.5, Iss.1, 2005-01, pp. : 41-50

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Antihypertensive Efficacy of Olmesartan Medoxomil and Candesartan Cilexetil Assessed by 24-Hour Ambulatory Blood Pressure Monitoring in Patients with Essential Hypertension

By Brunner H.R.  

Clinical Drug Investigation, Vol. 23, Iss. 7, 2003-01 ,pp. : 419-430

Adis International

Access to resources Recommend Favorite

Antihypertensive Efficacy of Olmesartan Medoxomil and Candesartan Cilexetil in Achieving 24-Hour Blood Pressure Reductions and Ambulatory Blood Pressure Goals

By Brunner Hans R.  

Clinical Drug Investigation, Vol. 26, Iss. 4, 2006-01 ,pp. : 185-193

Adis International

Access to resources Recommend Favorite

Olmesartan Medoxomil-Based Antihypertensive Therapy Evaluated by Ambulatory Blood Pressure Monitoring: Efficacy in High-Risk Patient Subgroups

By Chrysant Steven G.  

American Journal of Cardiovascular Drugs, Vol. 12, Iss. 6, 2012-12 ,pp. : 375-389

Adis International

Access to resources Recommend Favorite

Ambulatory Blood Pressure Comparison of the Anti-hypertensive Efficacy of Fixed Combinations of Irbesartan/hydrochlorothiazide and osartan/hydrochlorothiazide in Patients with Mild-to-moderate Hypertension

By Neutel JM   Smith D  

The Journal of International Medical Research, Vol. 33, Iss. 6, 2005-11 ,pp. : 620-631

Field House Publishing

Access to resources Recommend Favorite

Comparative Cost Effectiveness of Angiotensin II Receptor Blockers in a US Managed Care Setting: Olmesartan Medoxomil Compared with Losartan, Valsartan, and Irbesartan

By Simons W.R.  

PharmacoEconomics, Vol. 21, Iss. 1, 2003-01 ,pp. : 61-74

Adis International

Access to resources Recommend Favorite